Oklo announced the signing of a U.S. Department of Energy Other Transaction Agreement to design, construct, and operate a radioisotope pilot facility under the DOE Reactor Pilot Program.
The pilot will be built by Oklo’s subsidiary Atomic Alchemy Inc., which the company acquired in March 2025, and will produce isotopes for cancer diagnostics, disease treatment, scientific research, and national‑security applications.
The OTA marks a transition from planning to active execution, removing a key regulatory hurdle and positioning Oklo to establish a domestic supply chain for critical medical isotopes, thereby reducing reliance on overseas production and aging facilities.
The pilot facility leverages Oklo’s fast‑reactor technology, which generates excess neutrons ideal for isotope production, creating synergies with its Aurora microreactor and fuel‑recycling capabilities.
Oklo had previously been selected for three projects under the DOE Reactor Pilot Program in August 2025, with criticality expected by July 4 2026; the OTA provides the framework for design, construction, and operation of the pilot plant.
CEO Jacob DeWitte said the OTA “establishes a framework for execution and risk reduction” and that building and operating the pilot will generate data to streamline future commercial deployments and improve regulatory efficiency.
The agreement follows the withdrawal of Atomic Alchemy’s NRC construction‑permit application for the Meitner‑1 commercial facility, underscoring the company’s focus on the DOE‑backed pilot path.
With a cash reserve of nearly $1.2 billion and a high current ratio, Oklo is well positioned to fund the capital‑intensive pilot while maintaining financial flexibility.
The move is part of a broader strategy to diversify beyond power generation, tapping a $55.7 billion radioisotope market projected to grow through 2026, and to strengthen U.S. energy security and healthcare infrastructure.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.